← Back to Search

Unknown

ABBV-CLS-7262 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Calico Life Sciences LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up two weeks
Awards & highlights

Study Summary

This trial tests a combination of drugs to treat heart disease. Patients take rosuvastatin, digoxin, and ABBV-CLS-7262 in two periods.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~two weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and two weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pharmacokinetics of Digoxin
Pharmacokinetics of Rosuvastatin
Secondary outcome measures
Safety and Tolerability

Trial Design

1Treatment groups
Experimental Treatment
Group I: ABBV-CLS-7262Experimental Treatment1 Intervention
ABBV-CLS-7262 + Digoxin + Rosuvastatin
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ABBV-CLS-7262
2023
Completed Phase 1
~30

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Calico Life Sciences LLCLead Sponsor
8 Previous Clinical Trials
946 Total Patients Enrolled
AbbVieIndustry Sponsor
954 Previous Clinical Trials
501,032 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experiment permit individuals under 30 years of age to participate?

"To be eligible, patients must not have exceeded the age of 65 and surpassed the legally recognised age of consent."

Answered by AI

Are enrollees being accepted for the current trial?

"Affirmative. Clinicaltrials.gov verifies that this study, which opened for recruitment on March 24th 2023, is still actively seeking participants. This trial needs approximately 12 volunteers from a single medical centre to reach completion."

Answered by AI

Who meets the criteria to be enrolled in this trial?

"To be eligible for this trial, participants must demonstrate sound health and situate themselves within the age range of 18-65. The recruitment is planned to encompass 12 individuals in total."

Answered by AI

Is ABBV-CLS-7262 deemed a secure remedy for individuals?

"Due to the preliminary nature of this study, our team has assigned ABBV-CLS-7262 a score of 1 on the safety scale. This indicates that there is limited evidence confirming efficacy and safety at this stage."

Answered by AI

How many participants are there in this trial?

"Affirmative. According to data on clinicaltrials.gov, this medical trial first appeared on March 24th 2023 and was last updated April 7th of the same year. The study demands 12 participants be recruited from a single site."

Answered by AI

Who else is applying?

What state do they live in?
Wisconsin
What site did they apply to?
AbbVie Clinical Pharmacology Research Unit (ACPRU)
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0
Recent research and studies
clinicaltrials.govStudy
A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects
2023. "A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05763459.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top